First Time Loading...

Y-mAbs Therapeutics Inc
NASDAQ:YMAB

Watchlist Manager
Y-mAbs Therapeutics Inc Logo
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Watchlist
Price: 12.28 USD -4.58% Market Closed
Updated: May 13, 2024

Gross Margin
Y-mAbs Therapeutics Inc

86.5%
Current
77%
Average
62.3%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
86.5%
=
Gross Profit
73.1m
/
Revenue
84.5m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
US
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
538.5m USD
87%
US
Abbvie Inc
NYSE:ABBV
283.9B USD
66%
US
Amgen Inc
NASDAQ:AMGN
166.4B USD
66%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
108.9B USD
87%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
107.3B USD
86%
AU
CSL Ltd
ASX:CSL
134.9B AUD
52%
US
Gilead Sciences Inc
NASDAQ:GILD
82.2B USD
76%
US
Moderna Inc
NASDAQ:MRNA
44.9B USD
22%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
75%
US
Biogen Inc
NASDAQ:BIIB
32.3B USD
75%
KR
Celltrion Inc
KRX:068270
40T KRW
48%
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Country US
Market Cap 538.5m USD
Gross Margin
87%
Abbvie Inc
NYSE:ABBV
Country US
Market Cap 283.9B USD
Gross Margin
66%
Amgen Inc
NASDAQ:AMGN
Country US
Market Cap 166.4B USD
Gross Margin
66%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Country US
Market Cap 108.9B USD
Gross Margin
87%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Country US
Market Cap 107.3B USD
Gross Margin
86%
CSL Ltd
ASX:CSL
Country AU
Market Cap 134.9B AUD
Gross Margin
52%
Gilead Sciences Inc
NASDAQ:GILD
Country US
Market Cap 82.2B USD
Gross Margin
76%
Moderna Inc
NASDAQ:MRNA
Country US
Market Cap 44.9B USD
Gross Margin
22%
Seagen Inc
NASDAQ:SGEN
Country US
Market Cap 43.1B USD
Gross Margin
75%
Biogen Inc
NASDAQ:BIIB
Country US
Market Cap 32.3B USD
Gross Margin
75%
Celltrion Inc
KRX:068270
Country KR
Market Cap 40T KRW
Gross Margin
48%

Profitability Report

View the profitability report to see the full profitability analysis for Y-mAbs Therapeutics Inc.

Full Profitability Report

See Also

Summary
YMAB intrinsic value, competitors valuation, and company profile.
DCF Valuation
YMAB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
YMAB stock valuation using valuation multiples.
Wall Street Estimates
YMAB price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
YMAB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
86.5%
=
Gross Profit
73.1m
/
Revenue
84.5m
What is the Gross Margin of Y-mAbs Therapeutics Inc?

Based on Y-mAbs Therapeutics Inc's most recent financial statements, the company has Gross Margin of 86.5%.

ALPHA SPREAD
Join more than 136,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.